Cost-effectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease

Published:2006-10-01 Issue:10 Volume:160 Page:1070
ISSN:1072-4710
Container-title:Archives of Pediatrics & Adolescent Medicine
language:en
Short-container-title:Arch Pediatr Adolesc Med

Author:

ElHassan Nahed O.,Sorbero Melony E. S.,Hall Caroline B.,Stevens Timothy P.,Dick Andrew W.

Publisher

American Medical Association (AMA)

Subject

Pediatrics, Perinatology and Child Health

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy;Journal of the Pediatric Infectious Diseases Society;2024-07-12

2. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia;BMC Infectious Diseases;2024-04-19

3. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States;Pediatrics & Neonatology;2023-09

4. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia;2023-08-04

5. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection;Pediatrics;2023-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP